What drove the earnings decline in FY26?

Revenue contracted by approximately 10%, and net profit fell by a sharper 17% on a year-on-year basis. The filing does not break out specific cost drivers behind the margin squeeze.

How does the dividend compare to last year?

The board recommended ₹1.50 per share. The filing does not state the prior year's payout, so a direct comparison is not possible from this document alone.

Were there any major board changes?

An independent director resigned, and a whole-time director was reappointed. Both are described as routine governance actions with no stated strategic implications.

Is this the first sign of a slowdown?

No. The rationale notes the decline is consistent with earlier trends, suggesting the earnings pressure has been building across multiple quarters.

Earnings · Pharmaceuticals · Micro cap

Haleos Labs' FY26 profit drops 17% on 10% revenue slide

The annual results show a moderate, consistent earnings decline. A ₹1.50 dividend is maintained.

HALEOSLABS By Tipsheet Editorial 30 May 2026 · 2:25 PM IST Verify on BSE · NSE

Mkt cap₹478 cr

P/E24.08×

ROE10.23%

Debt / eq.0.43

Div yld0.09%

-17% YoY Fall in Haleos Labs' standalone net profit for FY26.

What's new

Haleos Labs' FY2026 standalone revenue fell ~10% and net profit dropped ~17% year-on-year.
The board has recommended a final dividend of ₹1.50 per share.
Governance was routine: an independent director resigned, a whole-time director was reappointed.

Why this matters

The decline is moderate and in line with prior quarters. It removes any lingering ambiguity from interim numbers but also offers no signal of a near-term turnaround. The dividend, while maintained, is the only concession to shareholders in a year of shrinking profits.

What we're watching

Whether the trend stabilises in the next quarter's interim results.
Any shift in dividend policy if profits continue to slide.
Management's commentary on demand drivers in the earnings concall.

The full read

Haleos Labs' audited FY2026 numbers are in. Standalone revenue dropped ~10% and net profit fell 17% year-on-year. The board recommended a dividend of ₹1.50 per share. No surprises. The filing confirms the moderate, persistent earnings slide seen in interim quarters, with no quantified one-off events to explain the drop. A 17% profit decline on a 10% revenue fall points to margin pressure. The dividend is maintained. The board changes are routine. For investors, this is the annual scorecard they already had a preview of.

Questions answered

What drove the earnings decline in FY26?: Revenue contracted by approximately 10%, and net profit fell by a sharper 17% on a year-on-year basis. The filing does not break out specific cost drivers behind the margin squeeze.
How does the dividend compare to last year?: The board recommended ₹1.50 per share. The filing does not state the prior year's payout, so a direct comparison is not possible from this document alone.
Were there any major board changes?: An independent director resigned, and a whole-time director was reappointed. Both are described as routine governance actions with no stated strategic implications.
Is this the first sign of a slowdown?: No. The rationale notes the decline is consistent with earlier trends, suggesting the earnings pressure has been building across multiple quarters.

Mentioned: Haleos Labs Ltd. · ₹1.50 dividend · FY2026

Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.